ClinicalTrials.gg
RecruitingNCT06674460TASTE-SVDUpdated Oct 29, 2026

Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

A Phase 3 interventional study of Edaravone Dexborneol Sublingual Tablets and Placebo in Cerebral Small Vessel Disease and Ischemic Stroke, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Peking Union Medical College Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 29, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.

Planned enrollment
4th of 26
600 · median 105
Started
2025
with 5 others
Phase 3
2 of 48
1 open now
Primary completion
2027-10
later than 16 of 32 live
Registered
38th of 48
by date
Lead sponsor
2 of 48
Peking Union Medical College Hospital

Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 4th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2025, is one of 2 in phase 3, reaches primary completion later than 16 of the 32 other live ones, and was the 38th registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Cerebral Small Vessel Diseases with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel disease (TASTE-SVD).

The study will enroll approximately 600 participants aged 30 to 80 years who have experienced a recent small subcortical infarct (RSSI) and concomitant moderate-to-severe white matter hyperintensities (WMH) confirmed by MRI. Participants will be randomized in a 1:1 ratio into either the Edaravone Dexborneol Sublingual Tablets group or the placebo group, with a 24-week treatment period.

The primary endpoint is a hierarchical composite endpoint at week 24, including all-cause mortality, modified Rankin Scale (mRS) score ≥2, recurrent stroke, changes in MoCA score, and changes in VaDAS-Cog score.

Secondary endpoints include additional functional and cognitive assessments at week 24. Safety assessments will include all-cause mortality, adverse event (AE), treatment-related adverse event (TRAE), and serious adverse event (SAE).

The study aims to determine whether Edaravone Dexborneol Sublingual Tablets improve functional outcomes and cognitive performance in patients with small vessel disease-related stroke.

Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel disease (TASTE-SVD).

  1. Background and Rationale Cerebral small vessel disease (CSVD) is a major contributor to stroke, cognitive decline, and disability. Currently, there are no approved targeted therapies specifically addressing the pathophysiology of CSVD-related ischemic stroke. Edaravone Dexborneol, a novel free radical scavenger and anti-inflammatory agent, has shown neuroprotective effects in preclinical models and clinical trials for ischemic stroke. The TASTE-SL trial demonstrated that Edaravone Dexborneol improved functional outcomes at 90 days in acute ischemic stroke patients.
  2. Study Design and Methods A total of 600 participants will be recruited across 50 clinical sites in China. Participants must be 30-80 years old and have an MRI-confirmed recent small subcortical infarct (RSSI) and concomitant moderate-to-severe white matter hyperintensities (WMH).

    Eligible participants will be randomized 1:1 into:

    • Treatment group: Edaravone Dexborneol Sublingual Tablets (Edaravone 30 mg + Dexborneol 6 mg), twice daily for 24 weeks.
    • Control group: Placebo, twice daily for 24 weeks.
  3. Study Endpoints 3.1 Primary Efficacy Endpoint

A hierarchical composite endpoint including:

  1. All-cause mortality
  2. Modified Rankin Scale (mRS) score ≥2
  3. Recurrent stroke
  4. Change in MoCA score from baseline
  5. Change in VaDAS-Cog score from baseline

3.2 Secondary Efficacy Endpoints

  1. Hierarchical composite endpoint: all-cause mortality, mRS≥2, or recurrent stroke
  2. All-cause mortality
  3. Functional disability, defined as a mRS≥2
  4. Recurrent stroke
  5. Proportion of patients with post-stroke cognitive impairment, defined as a MoCA score \<22
  6. Change in Mini-Mental State Examination (MMSE) score from baseline
  7. Change in MoCA score from baseline
  8. Change in VaDAS-Cog score from baseline
  9. Change in Hamilton Depression Scale score from baseline
  10. Change in IADL score from baseline

3.3 Safety Endpoints

  1. Serious adverse event (SAE)
  2. All-cause mortality
  3. Adverse event (AE)
  4. Treatment-related adverse event (TRAE)

4. Statistical Analysis The primary analysis will use the Win Ratio method to compare hierarchical composite endpoints between treatment groups. Secondary analyses will assess prespecified clinical, cognitive, and safety outcomes using methods tailored to their data types, including the win ratio, modified Poisson regression, mixed-effects models, linear regression, Kaplan-Meier and Cox models, and Poisson regression.

5. Significance This study aims to determine whether Edaravone Dexborneol Sublingual Tablets can improve functional outcomes, prevent cognitive decline, and reduce stroke recurrence in CSVD-related ischemic stroke. If successful, the findings may support a new treatment approach for this high-risk population.

03

Conditions studied

  • Cerebral Small Vessel Disease
  • Ischemic Stroke

Keywords

  • sublingual edaravone dexborneol
  • cerebral small vessel disease
  • acute ischemic cerebral small vessel disease
  • cognition
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

1. Inclusion Criteria:

  1. Age: Between 30 and 80 years .
  2. MRI-confirmed recent small subcortical infarct (RSSI): A lesion in the small penetrating artery territory, detected as DWI hyperintensity and ADC hypointensity, with a maximum axial diameter ≤20 mm.
  3. White Matter Hyperintensity (WMH) Burden: Fazekas score ≥2 (total score range: 0-6).
  4. Time from Stroke Onset: ≤3 weeks from symptom onset to randomization.
  5. Pre-stroke Functional Status: Modified Rankin Scale (mRS) ≤1 before the index stroke.
  6. Cognitive Function: No prior diagnosis of cognitive impairment or dementia.
  7. Education Level: At least primary school education and capable of completing cognitive assessments as judged by the investigator.
  8. Requirements:Women of and male participants with female partners of childbearing potential must agree to use effective contraception during the study and 30 days after the last dose of the drug.Female participants must have a negative pregnancy test before enrollment.
  9. : Participants or their legal representatives must voluntarily sign an informed consent form (ICF).

2. Exclusion Criteria:

  1. Intracranial Hemorrhagic Diseases: Evidence of hemorrhagic stroke, epidural hematoma, subarachnoid hemorrhage, or other bleeding disorders detected by head imaging (MRI/CT).However, hemorrhagic transformation may be assessed by the investigator for potential inclusion.
  2. Severe Consciousness Disturbance: NIHSS item 1a score >1 (indicative of significant impairment in consciousness).
  3. Cortical Infarcts or Other Brain Abnormalities:Co-existing cortical infarcts, hydrocephalus, or other non-vascular white matter diseases (e.g., multiple sclerosis, carbon monoxide poisoning-related leukoencephalopathy).
  4. Severe Carotid Artery Stenosis: Requiring surgical intervention (>50% stenosis).
  5. Systemic Conditions Affecting Cognition:Endocrine disorders, vitamin deficiencies, systemic diseases that can cause cognitive impairment.
  6. Neurological Disorders Associated with Cognitive Decline:CNS infections, Creutzfeldt-Jakob disease, primary Parkinson's disease, epilepsy, brain tumors, or severe traumatic brain injury.
  7. Pre-existing Severe Psychiatric Disorders:Diagnosed with major depressive disorder, vascular cognitive impairment, Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, frontotemporal dementia, or any cognitive dysfunction unrelated to stroke.
  8. Severe Physical Disability or Language Impairment:Severe hemiplegia or aphasia that significantly affects cognitive assessment.
  9. Use of Cognitive-Enhancing Medications:Within 4 weeks prior to screening, including but not limited to:Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine),Other neuroprotective agents (sodium oligomannate, lecanemab)
  10. Severe Liver or Kidney Dysfunction:Active liver disease (acute hepatitis, chronic active hepatitis, cirrhosis) or /AST >2× .
  11. Severe renal impairment (serum creatinine >1.5× ULN).
  12. \<1 year due to severe systemic diseases.
  13. to MRI:Participants with MRI-incompatible implants, severe claustrophobia, or inability to undergo MRI.
  14. Known Allergies:History of to Dexborneol, natural borneol, edaravone, or any (e.g., mannitol, copovidone, microcrystalline cellulose, silica, magnesium stearate).
  15. Pregnancy and Lactation:Pregnant or lactating women, or those planning pregnancy during the study period.
  16. Participation in Other Clinical Trials:Enrolled in another clinical trial within the last 30 days.
  17. Other Investigator-Determined Factors:Any other medical, psychological, or social condition that, in the investigator's judgment, makes the patient unsuitable for participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Edaravone Dexborneol Sublingual Tablets

    One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.

    Drug: Edaravone Dexborneol Sublingual Tablets

  • Placebo comparator
    Placebo

    One placebo tablet, to be taken sublingually, twice daily.

    Drug: Placebo

Interventions

  • DrugEdaravone Dexborneol Sublingual Tablets

    One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.

  • DrugPlacebo

    One placebo tablet, to be taken sublingually, twice daily

06

What researchers measure

Primary outcomes

  1. Hierarchical Composite Endpoint

    This composite outcome consists of five hierarchical endpoints at 24 weeks, analyzed using the Win Ratio method: 1. All-Cause Mortality 2. Modified Rankin Scale (mRS) Score ≥2 3. Stroke Recurrence 4. Change in Montreal Cognitive Assessment (MoCA) Score from Baseline 5. Change in Vascular Dementia Assessment Scale-Cognitive Subscale (VaDAS-Cog) Score from Baseline. The Win Ratio approach will be used to analyze these outcomes in order of priority.

    Time frame: 24 weeks

Secondary outcomes

  1. Hierarchical composite endpoint

    Hierarchical composite endpoint comprising all-cause mortality, mRS ≥2, and stroke recurrence.The hierarchy of composite endpoint of all-cause mortality, mRS≥2, recurrent stroke at 24 weeks will be analysed using a win ratio method.

    Time frame: 24 weeks

  2. All cause mortality

    The number of participants who experience all-cause mortality at 24 weeks. All-cause mortality includes death from any reason, such as cardiovascular, neurological, or other systemic causes. This measure is used to assess the overall survival impact of the intervention.

    Time frame: 24 weeks

  3. Modified Rankin Scale (mRS) Score ≥2

    The proportion of participants with a modified Rankin Scale (mRS) score ≥2 at 24 weeks. The mRS is a widely used functional outcome measure that assesses the degree of disability or dependence in daily activities following a stroke. The scale ranges from 0 (no symptoms) to 6 (death), with scores of 2 or higher indicating functional dependence. A higher proportion of participants with mRS ≥2 suggests a worse functional outcome.

    Time frame: 24 weeks

  4. Stroke recurrence

    The number of participants who experience a recurrent stroke within 24 weeks of treatment. Recurrent stroke is defined as a new ischemic or hemorrhagic stroke occurring after the initial qualifying event, confirmed by neurological symptoms lasting ≥24 hours and neuroimaging evidence (MRI or CT). This measure assesses the effectiveness of the intervention in preventing subsequent strokes

    Time frame: 24 weeks

  5. Post-stroke cognitive impairment

    Number of participants with post-stroke cognitive impairment, defined as a MOCA score \< 22

    Time frame: 24 weeks

  6. Cognitive function (MMSE)

    Changes in Mini-Mental State Examination (MMSE) score from baseline. MMSE includes the assessment of 11 cognitive functions, which encompass orientation, registration of information, attention/calculation abilities, recall, naming, repetition, comprehension (both verbal and written), writing, and visuospatial construction skills. The MMSE scale ranges from 0 to 30 points, with higher scores indicating a better outcome.

    Time frame: 24 weeks

  7. Cognitive function (MoCA)

    The change in Montreal Cognitive Assessment (MoCA) scores from baseline to 24 weeks of treatment. The MoCA is a cognitive screening tool that assesses multiple domains, including attention, concentration, executive function, memory, language, visuospatial skills, abstract thinking, calculation, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive function. A greater positive change from baseline represents an improvement in cognitive function.

    Time frame: 24 weeks

  8. Cognitive function (VaDAS-Cog)

    Changes in Vascular Dementia Assessment Scale-Cognitive (VaDAS-Cog) score from baseline. The VaDAS-Cog is a neuropsychological assessment tool specifically designed to evaluate cognitive impairments associated with vascular dementia. VaDAS-Cog was created by adding five subtests to the ADAS-Cog that reflect attention and executive functions. The total score ranges from 0 to 70, with lower scores indicating lesser severity.

    Time frame: 24 weeks

  9. Depression (HAMD)

    Changes in Hamilton Depression Rating Scale (HAMD) score from baseline. The HAMD is a widely used clinical tool for assessing the severity of depression. It consists of multiple items that evaluate various aspects of depressive symptoms, including mood, guilt, suicidal ideation, work and interest, among others. It is scored on a scale from 0 to 52, with higher scores indicating more severe symptoms.

    Time frame: 24 weeks

  10. Activity of Daily Living

    Changes in Instrumental Activities of Daily Living (IADL) score from baseline.IADL are activities that support daily life and are oriented toward interacting with your environment. Common IADLs include: Care of others; Care of pets; Child rearing; Communication management; Driving and community mobility; Financial management; Health management and maintenance; Home establishment and management; Meal preparation and clean up; Religious and spiritual activities and expressions; Safety procedure and emergency responses; Shopping. It is scored on a scale from 0 to 31, with higher scores indicating more severe symptoms.

    Time frame: 24 weeks

  11. Serious adverse events

    Serious adverse events, confirmed by the Clinical Event Committee.

    Time frame: 24 weeks

  12. Adverse events

    Adverse events, confirmed by the Clinical Event Committee.

    Time frame: 24 weeks

  13. Treatment-related adverse events

    Treatment-related adverse events, confirmed by the Clinical Event Committee.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, Ren J, Yang S, Chen R, Zhu S, Feng X, Yao J, Wei Y, Dong X, Ling Y, Yi F, Deng Q, Guo C, Sui Y, Han S, Wen G, Li C, Dong A, Sun X, Wang Z, Shi X, Liu B, Fan D. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024 Feb 19;81(4):319-26. doi: 10.1001/jamaneurol.2023.5716. Online ahead of print. PubMed 38372981 ↗
  • Xu J, Wang Y, Wang A, Gao Z, Gao X, Chen H, Zhou J, Zhao X, Wang Y. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019 Apr 22;4(3):109-114. doi: 10.1136/svn-2018-000221. eCollection 2019 Sep. PubMed 31709115 ↗
  • Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, Chen H, Ji Y, Xu J, Geng D, Zhu R, Liu B, Dong A, Mu H, Lu Z, Li S, Zheng H, Chen X, Wang Y, Zhao X, Wang Y; TASTE Trial Investigatorsdagger. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. 2021 Mar;52(3):772-780. doi: 10.1161/STROKEAHA.120.031197. Epub 2021 Feb 16. PubMed 33588596 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Nov 5, 2024
StartActual
Aug 1, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
5 removed, 1 description edited
What changed in the outcomes
  • RemovedAll-Cause MortalityTime frame: 24weeks
  • RemovedModified Rankin Scale (mRS) Score ≥2Time frame: 24 weeks
  • RemovedStroke RecurrenceTime frame: 24 weeks
  • RemovedChange in Montreal Cognitive Assessment (MoCA) Score from BaselineTime frame: 24 weeks
  • RemovedChange in Vascular Dementia Assessment Scale-Cognitive Subscale (VaDAS-Cog) Score from BaselineTime frame: 24 weeks
  • DescriptionHierarchical Composite Endpoint: how it is measured was reworded
Oct 29, 2026
Secondary outcomes
2 edited, 20 removed
What changed in the outcomes
  • EditedCompositeHierarchical composite endpointTime frame: 24 weeks
  • EditedAdverseTreatment-related adverse eventsTime frame: 52weeks → 24 weeks
  • RemovedLiver function impairmentTime frame: 24 weeks
  • RemovedRenal function impairmentTime frame: 24 weeks
  • RemovedChange in White Matter Hyperintensity Fazekas Score from BaselineTime frame: 52 weeks
  • RemovedNumber of New MRI-Confirmed InfarctsTime frame: 52 weeks
  • RemovedChange in Number of Microbleeds from BaselineTime frame: 52 weeks
  • RemovedChange in White Matter Hyperintensity Volume from BaselineTime frame: 52 weeks
  • RemovedChange in Brain Atrophy Index from BaselineTime frame: 52 weeks
  • RemovedAll cause mortalityTime frame: 52weeks
  • RemovedModified Rankin Scale (mRS) Score ≥2Time frame: 52weeks
  • RemovedStroke recurrenceTime frame: 52 weeks
  • RemovedPost-stroke cognitive impairmentTime frame: 52weeks
  • RemovedCognitive function (MMSE)Time frame: 52weeks
  • RemovedCognitive function (MoCA)Time frame: 52weeks
  • RemovedCognitive function (VaDAS-Cog)Time frame: 52weeks
  • RemovedDepression (HAMD)Time frame: 52weeks
  • RemovedActivity of Daily LivingTime frame: 52weeks
  • RemovedSerious adverse eventsTime frame: 52weeks
  • RemovedLiver function impairmentTime frame: 52weeks
  • RemovedRenal function impairmentTime frame: 52weeks
  • RemovedComposite endpointTime frame: 52weeks
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary outcomes 5 removed, 1 description edited
    What changed in the outcomes
    • RemovedAll-Cause MortalityTime frame: 24weeks
    • RemovedModified Rankin Scale (mRS) Score ≥2Time frame: 24 weeks
    • RemovedStroke RecurrenceTime frame: 24 weeks
    • RemovedChange in Montreal Cognitive Assessment (MoCA) Score from BaselineTime frame: 24 weeks
    • RemovedChange in Vascular Dementia Assessment Scale-Cognitive Subscale (VaDAS-Cog) Score from BaselineTime frame: 24 weeks
    • DescriptionHierarchical Composite Endpoint: how it is measured was reworded
    Secondary outcomes 2 edited, 20 removed
    What changed in the outcomes
    • EditedCompositeHierarchical composite endpointTime frame: 24 weeks
    • EditedAdverseTreatment-related adverse eventsTime frame: 52weeks → 24 weeks
    • RemovedLiver function impairmentTime frame: 24 weeks
    • RemovedRenal function impairmentTime frame: 24 weeks
    • RemovedChange in White Matter Hyperintensity Fazekas Score from BaselineTime frame: 52 weeks
    • RemovedNumber of New MRI-Confirmed InfarctsTime frame: 52 weeks
    • RemovedChange in Number of Microbleeds from BaselineTime frame: 52 weeks
    • RemovedChange in White Matter Hyperintensity Volume from BaselineTime frame: 52 weeks
    • RemovedChange in Brain Atrophy Index from BaselineTime frame: 52 weeks
    • RemovedAll cause mortalityTime frame: 52weeks
    • RemovedModified Rankin Scale (mRS) Score ≥2Time frame: 52weeks
    • RemovedStroke recurrenceTime frame: 52 weeks
    • RemovedPost-stroke cognitive impairmentTime frame: 52weeks
    • RemovedCognitive function (MMSE)Time frame: 52weeks
    • RemovedCognitive function (MoCA)Time frame: 52weeks
    • RemovedCognitive function (VaDAS-Cog)Time frame: 52weeks
    • RemovedDepression (HAMD)Time frame: 52weeks
    • RemovedActivity of Daily LivingTime frame: 52weeks
    • RemovedSerious adverse eventsTime frame: 52weeks
    • RemovedLiver function impairmentTime frame: 52weeks
    • RemovedRenal function impairmentTime frame: 52weeks
    • RemovedComposite endpointTime frame: 52weeks
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06674460
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Aug 1, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

YiCheng Zhu, Doctor
Contact
zhuych910@163.com
(+86)01069156380

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion